Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879017 · ClinicalTrials.gov registry record · Phase 1
FHD-286 in Subjects With Metastatic Uveal Melanoma
A Phase 1 study, sponsored by Foghorn Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT04879017: Clinical Trial Phase 1 study, sponsored by Foghorn Therapeutics.
NCT04879017 is a Phase 1 study that was terminated before completion, run by Foghorn Therapeutics. The registered enrollment target is 76 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04879017, a Phase 1 study, was terminated before completion, sponsored by Foghorn Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
Primary Outcome
Dose escalation and expansion
Interventions
- DRUG FHD-286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 1 |
Why NCT04879017 stopped before completion
NCT04879017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% higher).
The record links to 0 conditions, and to 1 intervention - of which FHD-286 is the first listed.
NCT04879017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04879017 about?
NCT04879017 is a clinical study titled "FHD-286 in Subjects With Metastatic Uveal Melanoma". This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
What is the current status of trial NCT04879017?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2021-05-11. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04879017?
The interventions under investigation include: FHD-286 (DRUG).
Who is sponsoring clinical trial NCT04879017?
This trial is sponsored by Foghorn Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04879017's enrollment target sits among peer trials
76 705th of 2000 higher than 1,290 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI